The gene-activated bone substitute ("Histograft") comprises OCP granules (with diameters of 50-150, 150–500, 500-1000, 1000-2000 μm) with molecules of pDNA-VEGF (under the CMV promoter), the active substance in Neovasculgen (HSCI, Russia), at 100 μg/g of OCP. OCP and pDNA-VEGF are combined using the original technology described in patent application US 20190224379A1. The product is manufactured in Russian Federation as sterile lyophilized gene-activated bone substitute at 0.5, 1.0, 2.0 and 5.0g, is stored in glass vials, and kept at a temperature of 2–6°C. The final dosage of pDNA-VEGF is 100 μg/g (≅1.0 cm3) of OCP.